# Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations

> **NCT03786796** · PHASE2 · RECRUITING · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 20 (estimated)

## Conditions studied

- Renal Cell Carcinoma
- Metastatic Renal Cell Carcinoma
- Kidney Cancer
- Renal Carcinoma
- Kidney Cancer Metastatic

## Interventions

- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT03786796
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-06-03
- **Primary completion:** 2027-03
- **Final completion:** 2028-03
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-03-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03786796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03786796, "Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03786796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*